Nirmatrelvir + ritonavir

1. Nirmatrelvir + ritonavir lowers the risk of diabetes mellitus in humans (absolute difference of -1.0% (95% CI, -1.25 to -0.73)).

   “Two years post infection, cumulative DM incidence was 2.1% with Paxlovid vs 3.1% without, an absolute difference of -1.0% (95% CI, -1.25 to -0.73).”

   HumansSARS-CoV-2 infection2 yearsn = 131,615

   Paxlovid Use for SARS-CoV-2 Infection and Two-Year Risk of Diabetes: The COVID-19 and Diabetes Assessment (CODA) Study

   ADA Scientific Sessions 2026 abstract·6 Jun 2026

More on Diabetes mellitus

1. Nirmatrelvir + ritonavir is associated with survival in humans.

   “These findings were externally validated in the US TriNetX network, where the same patterns were observed for atovaquone-proguanil, mefloquine, and nirmatrelvir-ritonavir.”

   Humansmultimorbid individuals with COVID-19

   Antiprotozoal medications associated with increased longevity and reduced morbidity in two national cohorts

   medRxiv : the preprint server for health sciences·30 Jul 2025Preprint